Search: onr:"swepub:oai:DiVA.org:uu-361107" >
Quality of life and...
Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases
-
- Cashin, Peter, 1984- (author)
- Uppsala universitet,Kolorektalkirurgi
-
- Mahteme, Haile, 1959- (author)
- Uppsala universitet,Kolorektalkirurgi,Uppsala Canc Clin, Uppsala, Sweden
-
- Syk, I. (author)
- Lund Univ, Sect Surg, Dept Clin Sci, Malmo, Sweden
-
show more...
-
- Frodin, J. E. (author)
- Karolinska Institutet
-
- Glimelius, Bengt (author)
- Uppsala universitet,Experimentell och klinisk onkologi,Karolinska Inst, Dept Oncol & Pathol, S-17176 Stockholm, Sweden
-
- Graf, Wilhelm (author)
- Uppsala universitet,Kolorektalkirurgi
-
show less...
-
(creator_code:org_t)
- ELSEVIER SCI LTD, 2018
- 2018
- English.
-
In: European Journal of Surgical Oncology. - : ELSEVIER SCI LTD. - 0748-7983 .- 1532-2157. ; 44:7, s. 983-990
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: The aim was to compare health-related quality-of-life (HRQOL) and cost-effectiveness between cytoreductive surgery with intraperitoneal chemotherapy (CRS + IPC) and systemic chemotherapy for patients with colorectal peritoneal metastases. Methods: Patients included in the Swedish Peritoneal Trial comparing CRS + IPC and systemic chemotherapy completed the EORTC QLQ-C30 and SF-36 questionnaires at baseline, 2, 4, 6, 12, 18, and 24 months. HRQOL at 24 months was the primary endpoint. EORTC sum score, SF-36 physical and mental component scores at 24 months were calculated and compared for each arm and then referenced against general population values. Two quality-adjusted life-year (QALY) indices were applied (EORTC-8D and SF-6D) and an incremental cost-effectiveness ratio (ICER) per QALY gained was calculated. A projected life-time ICER per QALY gained was calculated using predicted survival according to Swedish population statistics. Results: No statistical differences in HRQOL between the arms were noted at 24 months. Descriptively, survivors in the surgery arm had higher summary scores than the general population at 24 months, whereas survivors in the chemotherapy arm had lower scores. The projected life-time QALY benefit was 3.8 QALYs in favor of the surgery arm (p=0.06) with an ICER per QALY gained at 310,000 SEK (EORTC-8D) or 362,000 SEK (SF-6D) corresponding to 26,700-31,200 GBP. Conclusion: The HRQOL in patients with colorectal peritoneal metastases undergoing CRS + IPC appear similar to those receiving systemic chemotherapy. Two-year survivors in the CRS + IPC arm have comparable HRQOL to a general population reference. The treatment is cost-effective according to NICE guidelines.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Omvårdnad (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Nursing (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Colorectal cancer
- Peritoneal metastases
- Cytoreductive surgery
- Intraperitoneal chemotherapy
- Quality of life
- Cost-effectiveness
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database